Market Price

301.89 

3.23 0.6%

as of Dec 01 '22

52 Week Range:

240.10 307.82


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and CSL Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The CSL Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22
Equity (BVPS) 7.27
7.77
7.37
8.41
8.35
8.35
11.56
15.29
19.49
23.85
growth rate 6.9% -5.2% 14.1% -0.7% 0.0% 38.4% 32.3% 27.5% 22.4%
Earnings BIT 1,220.00
1,480.00
1,637.20
1,758.00
1,437.50
1,768.90
2,380.30
2,504.00
2,716.50
3,130.00
2,967.40
growth rate 21.3% 10.6% 7.4% -18.2% 23.1% 34.6% 5.2% 8.5% 15.2% -5.2%
Avg.PE 20.88
23.47
23.31
31.97
36.98
43.60
60.68
53.81
62.08
41.07
38.59
growth rate 12.4% -0.7% 37.2% 15.7% 17.9% 39.2% -11.3% 15.4% -33.8% -6.0%
ROA 17.69
20.39
21.33
21.75
17.79
16.03
17.38
16.62
15.14
14.13
growth rate 15.3% 4.6% 2.0% -18.2% -9.9% 8.4% -4.4% -8.9% -6.7%
ROE 27.17
37.34
42.37
46.68
46.76
46.67
47.74
41.12
35.70
31.86
growth rate 37.4% 13.5% 10.2% 0.2% -0.2% 2.3% -13.9% -13.2% -10.8%
ROIC 21.94
25.94
27.39
28.06
24.00
21.79
23.12
22.33
19.79
18.79
growth rate 18.2% 5.6% 2.5% -14.5% -9.2% 6.1% -3.4% -11.4% -5.1%
Cur. Ratio 3.62
3.60
3.79
3.57
2.78
2.84
2.61
2.53
3.01
2.38
growth rate -0.6% 5.3% -5.8% -22.1% 2.2% -8.1% -3.1% 19.0% -20.9%
Quick Ratio 2.03
1.74
1.80
1.62
1.16
1.21
1.14
1.08
1.29
1.09
growth rate -14.3% 3.5% -10.0% -28.4% 4.3% -5.8% -5.3% 19.4% -15.5%
Leverage 1.70
1.99
1.99
2.33
2.95
2.88
2.64
2.35
2.37
2.17
growth rate 17.1% 0.0% 17.1% 26.6% -2.4% -8.3% -11.0% 0.9% -8.4%
Balance Sheet Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22
Acct.Receivable 761.00
822.00
915.00
978.90
1,044.30
1,113.50
1,372.10
1,726.30
1,593.30
1,648.00
1,513.10
growth rate 8.0% 11.3% 7.0% 6.7% 6.6% 23.2% 25.8% -7.7% 3.4% -8.2%
Acct.Payable 221.00
261.00
213.90
257.80
303.50
399.00
417.40
422.60
458.30
523.00
591.80
growth rate 18.1% -18.1% 20.5% 17.7% 31.5% 4.6% 1.3% 8.5% 14.1% 13.2%
Cur.Assets 3,445.00
3,259.00
3,207.60
3,339.10
3,818.00
4,602.10
4,993.70
5,540.10
6,446.20
7,389.70
16,460.70
growth rate -5.4% -1.6% 4.1% 14.3% 20.5% 8.5% 10.9% 16.4% 14.6% 122.8%
Total Assets 5,901.00
5,974.00
6,277.70
6,401.00
7,562.70
9,122.70
10,774.50
12,314.40
15,615.50
18,156.90
28,346.00
growth rate 1.2% 5.1% 2.0% 18.2% 20.6% 18.1% 14.3% 26.8% 16.3% 56.1%
Cash 1,171.00
762.00
608.70
556.80
556.60
844.50
814.70
657.80
1,194.40
1,808.80
10,436.40
growth rate -34.9% -20.1% -8.5% 0.0% 51.7% -3.5% -19.3% 81.6% 51.4% 477.0%
Inventory 1,483.00
1,639.00
1,644.50
1,755.60
2,152.00
2,575.80
2,692.80
3,038.80
3,509.50
3,780.60
4,333.00
growth rate 10.5% 0.3% 6.8% 22.6% 19.7% 4.5% 12.9% 15.5% 7.7% 14.6%
Cur.Liabilities 950.00
907.00
845.30
936.10
1,374.40
1,618.10
1,914.70
2,188.20
2,141.50
3,103.60
7,108.20
growth rate -4.5% -6.8% 10.7% 46.8% 17.7% 18.3% 14.3% -2.1% 44.9% 129.0%
Liabilities 2,425.00
2,956.00
3,115.70
3,654.10
4,995.50
5,958.90
6,694.60
7,063.10
9,087.90
9,775.60
13,768.50
growth rate 21.9% 5.4% 17.3% 36.7% 19.3% 12.4% 5.5% 28.7% 7.6% 40.9%
LT Debt 1,096.00
1,650.00
1,858.90
2,254.90
3,058.70
3,830.40
4,140.10
4,222.70
4,824.70
4,213.90
3,854.50
growth rate 50.6% 12.7% 21.3% 35.7% 25.2% 8.1% 2.0% 14.3% -12.7% -8.5%
Equity 3,428.30
3,241.80
3,162.00
2,746.90
2,567.20
3,163.80
4,079.90
5,251.30
6,527.60
8,381.30
14,577.50
growth rate -5.4% -2.5% -13.1% -6.5% 23.2% 29.0% 28.7% 24.3% 28.4% 73.9%
Common Shares 520.00
500.00
486.00
472.00
463.00
456.00
454.00
454.00
456.00
456.00
4,988.40
growth rate -3.9% -2.8% -2.9% -1.9% -1.5% -0.4% 0.0% 0.4% 0.0% 994.0%
Cash Flow Statement Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22
Capital Expenditures 309.00
433.00
353.90
347.80
495.10
689.00
778.80
1,117.60
1,206.80
1,196.30
1,078.80
growth rate 40.1% -18.3% -1.7% 42.4% 39.2% 13.0% 43.5% 8.0% -0.9% -9.8%
Cash Dividends 422.10
538.40
521.50
535.40
579.00
601.30
672.20
806.80
883.10
958.00
1,038.70
growth rate 27.6% -3.1% 2.7% 8.1% 3.9% 11.8% 20.0% 9.5% 8.5% 8.4%
Cash From OA 1,206.00
1,312.00
1,360.70
1,363.60
1,178.60
1,246.60
1,902.10
1,644.40
2,488.30
3,621.90
2,628.70
growth rate 8.8% 3.7% 0.2% -13.6% 5.8% 52.6% -13.6% 51.3% 45.6% -27.4%
FCF per Share 1.73
1.94
1.62
3.03
2.69
1.34
1.41
1.55
2.90
6.69
growth rate 12.1% -16.5% 87.0% -11.2% -50.2% 5.2% 9.9% 87.1% 130.7%
Sale Purchase of Stock 17.80
34.70
17.40
12.70
growth rate 94.9% -49.9% -27.0%
FCF 869.00
862.00
958.00
949.00
612.00
386.00
910.00
360.00
1,121.00
1,954.00
1,549.90
growth rate -0.8% 11.1% -0.9% -35.5% -36.9% 135.8% -60.4% 211.4% 74.3% -20.7%
Income Statement Jun '12 Jun '13 Jun '14 Jun '15 Jun '16 Jun '17 Jun '18 Jun '19 Jun '20 Jun '21 Jun '22
Sales 4,616.00
4,950.00
5,334.80
5,458.60
6,115.30
6,947.00
7,915.30
8,538.60
9,150.80
10,310.00
10,561.90
growth rate 7.2% 7.8% 2.3% 12.0% 13.6% 13.9% 7.9% 7.2% 12.7% 2.4%
Op.Income 1,024.00
1,480.00
1,637.20
1,758.00
1,437.50
1,768.90
2,380.30
2,504.00
2,716.50
3,130.00
2,967.40
growth rate 44.5% 10.6% 7.4% -18.2% 23.1% 34.6% 5.2% 8.5% 15.2% -5.2%
IBT 1,216.80
1,582.10
1,604.30
1,714.00
1,555.90
1,689.80
2,281.20
2,341.10
2,572.70
2,963.10
2,779.60
growth rate 30.0% 1.4% 6.8% -9.2% 8.6% 35.0% 2.6% 9.9% 15.2% -6.2%
Net Income 1,024.00
1,211.00
1,307.00
1,379.00
1,242.40
1,337.40
1,728.90
1,918.70
2,102.50
2,375.00
2,254.70
growth rate 18.3% 7.9% 5.5% -9.9% 7.7% 29.3% 11.0% 9.6% 13.0% -5.1%
EPS 1.93
2.43
2.69
2.92
2.68
2.93
3.81
4.22
4.62
5.21
growth rate 25.9% 10.7% 8.6% -8.2% 9.3% 30.0% 10.8% 9.5% 12.8%
Gross Profit 2,227.00
2,559.00
2,730.80
2,852.70
3,062.50
3,617.60
4,383.70
4,777.40
5,226.40
5,843.30
5,732.30
growth rate 14.9% 6.7% 4.5% 7.4% 18.1% 21.2% 9.0% 9.4% 11.8% -1.9%
R&D 355.00
460.20
466.40
462.70
613.80
666.90
702.40
831.80
921.80
1,001.40
1,156.20
growth rate 29.6% 1.4% -0.8% 32.7% 8.7% 5.3% 18.4% 10.8% 8.6% 15.5%

Quarterly Statements

Item Name Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Earnings BIT 386.05
1,115.85
1,115.85
367.85
367.85
growth rate 189.0% 0.0% -67.0% 0.0%
Balance Sheet Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Acct.Receivable 1,648.00
2,313.70
2,313.70
1,513.10
1,513.10
growth rate 40.4% 0.0% -34.6% 0.0%
Acct.Payable 523.00
1,726.50
1,726.50
591.80
591.80
growth rate 230.1% 0.0% -65.7% 0.0%
Cur.Assets 7,389.70
12,457.30
12,457.30
16,460.70
16,460.70
growth rate 68.6% 0.0% 32.1% 0.0%
Total Assets 18,156.90
23,439.60
23,439.60
28,346.00
28,346.00
growth rate 29.1% 0.0% 20.9% 0.0%
Cash 1,808.80
6,334.30
6,334.30
10,436.40
10,436.40
growth rate 250.2% 0.0% 64.8% 0.0%
Inventory 3,780.60
3,806.60
3,806.60
4,333.00
4,333.00
growth rate 0.7% 0.0% 13.8% 0.0%
Cur.Liabilities 3,103.60
2,524.10
2,524.10
7,108.20
7,108.20
growth rate -18.7% 0.0% 181.6% 0.0%
Liabilities 9,775.60
9,406.40
9,406.40
13,768.50
13,768.50
growth rate -3.8% 0.0% 46.4% 0.0%
LT Debt 4,213.90
4,009.80
4,009.80
3,854.50
3,854.50
growth rate -4.8% 0.0% -3.9% 0.0%
Equity 8,381.30
14,033.20
14,033.20
14,577.50
14,577.50
growth rate 67.4% 0.0% 3.9% 0.0%
Common Shares 4,458.10
4,458.10
4,988.40
4,988.40
growth rate 0.0% 11.9% 0.0%
Cash Flow Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Capital Expenditures 315.75
262.50
262.50
276.90
276.90
growth rate -16.9% 0.0% 5.5% 0.0%
Cash Dividends 236.65
268.85
268.85
250.50
250.50
growth rate 13.6% 0.0% -6.8% 0.0%
Cash From OA 650.70
713.45
713.45
600.90
600.90
growth rate 9.6% 0.0% -15.8% 0.0%
Sale Purchase of Stock
growth rate
FCF 334.95
450.95
450.95
324.00
324.00
growth rate 34.6% 0.0% -28.2% 0.0%
Income Statement Jun '21 Sep '21 Dec '21 Mar '22 Jun '22
Sales 2,285.30
3,020.60
3,020.60
2,260.35
2,260.35
growth rate 32.2% 0.0% -25.2% 0.0%
Op.Income 386.05
1,115.85
1,115.85
367.85
367.85
growth rate 189.0% 0.0% -67.0% 0.0%
IBT 356.10
1,072.20
1,072.20
317.60
317.60
growth rate 201.1% 0.0% -70.4% 0.0%
Net Income 282.50
880.15
880.15
247.20
247.20
growth rate 211.6% 0.0% -71.9% 0.0%
Gross Profit 1,185.45
1,724.25
1,724.25
1,141.90
1,141.90
growth rate 45.5% 0.0% -33.8% 0.0%
R&D 287.05
242.90
242.90
335.20
335.20
growth rate -15.4% 0.0% 38.0% 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (79.63)

YOY Growth Grade:

C (54.04)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 41.81 41.81 30.43
EPS / Growth -3.0% 7.22 20.9%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 35.2%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 19.1% 19.1%
Future PE 2.00 36.78 36.78
Future EPS 7.98 41.29 41.29
Value Price
MOS %
3.94
-98.7%
375.38
24.3%
375.38
24.3%
MOS Price 1.97 187.69 187.69
IRT 34.81 11.68 11.68

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.